Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A.
David Weinreich, Head of Global Development, Specialty Medicine at Bayer declared: “With today’s announcement, we are thrilled to further strengthen our commitment to the hemophilia A patient community that Bayer has served for more than a quarter century.“
Bayer has a long history in hemophilia, with more than 25 years of research and development on products and approaches to meet varied needs of patients with hemophilia A. The new facility will be built at Bayer’s Berkeley manufacturing site.
Joerg Heidrich, Senior Vice President for Product Supply Biotech and Site Head at Bayer Berkeley explained: “As the Bay Area’s third largest biotech employer, we are also proud to be making this contribution to the world’s richest center of biotech R&D, investment, and production.“
Along with the new facility, this investment is expected to create 325,000 hours of jobs with local union contractors in trades ranging from glaziers to iron workers to sprinkler fitters.